Sign in to continue:

Friday, February 27th, 2026

BlackRock’s Share Dealings in ENN Energy Holdings Ltd During Privatisation Scheme – Public Disclosure Form 2026




BlackRock, Inc. Disclosure of Dealings in ENN ENERGY HOLDINGS LTD Shares

BlackRock, Inc. Disclosure of Dealings in ENN ENERGY HOLDINGS LTD Shares

Key Points from the Public Disclosure Form

  • Date of Disclosure: 26 February 2026
  • Context: Privatisation by way of scheme of arrangement for ENN ENERGY HOLDINGS LTD
  • Rule Invoked: Rule 22 of the Hong Kong Code on Takeovers and Mergers
  • Disclosing Party: BlackRock, Inc. (Class 6 associate of the Offeree company due to its shareholdings)
  • Nature of Dealings: All transactions were made for discretionary investment clients

Detailed Summary of Share Transactions

On 25 February 2026, BlackRock, Inc. engaged in multiple transactions involving the shares of ENN ENERGY HOLDINGS LTD. The following are the details of these trades:

Transaction Type Number of Shares Price per Share (USD) Resultant Balance Percentage of Class
Purchase 64,300 \$68.6500 64,140,037 5.6669%
Purchase 18,500 \$68.5949 64,158,537 5.6685%
Purchase 2,400 \$68.5438 64,160,937 5.6687%
Sale 28,364 \$68.6509 64,132,573 5.6662%
Purchase 259,000 \$68.6306 64,391,573 5.6891%
Sale 7,200 \$68.6500 64,384,373 5.6885%
Purchase 5,200 \$68.6183 64,389,573 5.6889%
Sale 30,780 \$68.6000 64,358,793 5.6862%
Purchase 72,200 \$68.5479 64,430,993 5.6926%

Important Shareholder Information

  • BlackRock, Inc.’s holdings in ENN ENERGY HOLDINGS LTD have increased to 64,430,993 shares, representing 5.6926% of the company’s share class.
  • The price range for these transactions was tightly clustered around \$68.54 to \$68.65 per share.
  • These movements are significant due to the ongoing privatisation by scheme of arrangement, which may impact share liquidity, pricing, and potential takeover dynamics.
  • BlackRock, Inc. remains a key stakeholder, and its trading activities could be interpreted as a vote of confidence in the company’s prospects during the privatisation process.
  • Frequent purchases and sales within a short timeframe suggest active portfolio management and possible anticipation of price changes related to the privatisation scheme.

Potential Price Sensitivity and Impact

The disclosed series of transactions by BlackRock, Inc.—one of the largest institutional investors—could be price sensitive, especially in the context of a privatisation scheme. Institutional buying at elevated prices may indicate expectations of a higher offer or value, while sales could signal profit-taking or risk management. Investors should be aware that the privatisation process and BlackRock’s dynamic trading could drive volatility and influence price direction in the near term.

Additional Notes

  • BlackRock, Inc. is a Class (6) associate, implying a direct interest in the outcome of the privatisation and potential influence over the process.
  • Transactions were carried out for discretionary investment clients, meaning the firm’s actions reflect broader institutional investor sentiment.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult professional advisors before making any investment decisions. The information is based on disclosed dealings and is subject to change as new developments emerge.




View ENN ENERGY Historical chart here



Dingdang Health Technology Group Announces Over 80% Reduction in FY2025 Net Loss and Turnaround to Profit

Dingdang Health Technology Group Ltd. Announces Significant Reduction in Losses and Turnaround to Profit for FY2025 Dingdang Health Technology Group Ltd. Issues Positive Profit Alert for FY2025 Key Highlights for Investors Significant Reduction in...

Prada S.p.A. Announces Board Meeting to Approve 2025 Annual Results and Final Dividend Recommendation 1

Prada S.p.A. Announces Upcoming Board Meeting to Approve 2025 Annual Results and Consider Final Dividend Prada S.p.A. Sets Date for Key Board Meeting to Approve 2025 Annual Results and Dividend Recommendation Prada S.p.A. (Stock...

Hangzhou Jiuyuan Genetic Biopharmaceutical’s Jikeqin Biosimilar Semaglutide Marketing Application Approved by NMPA for Weight Management 1

Hangzhou Jiuyuan Genetic Biopharmaceutical: Jikeqin® Marketing Application Approved by NMPA Hangzhou Jiuyuan Genetic Biopharmaceutical Announces Key Milestone for Jikeqin® Marketing Application for Biosimilar GLP-1 Receptor Agonist Accepted by NMPA Hangzhou Jiuyuan Genetic Biopharmaceutical Co.,...

   Ad